Intercept Pharma (ICPT) Estimates Raised At Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Intercept Pharma (ICPT) Estimates Raised At Baird
February 19, 2019 4:12 PM EST
Cowen analyst Ritu Baral raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $149.00 (from $120.00) while maintaining a Outperform rating.
The analyst commented, "ICPT's Ph3 NASH trial REGENERATE reported positive data this morning, achieving statistically significant fibrosis (with no... More
February 19, 2019 1:57 PM EST
Wedbush analyst Liana Moussatos raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $248.00 (from $220.00) while maintaining a Outperform rating.
...
More
February 19, 2019 1:03 PM EST
Oppenheimer analyst Jay Olson raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $175.00 (from $140.00) while maintaining a Outperform rating.
The analyst commented, "Top line results from the Ph3 REGENERATE study of OCA in NASH were stat sig for Fibrosis... More
February 19, 2019 10:42 AM EST
Needham & Company analyst Alan Carr reiterated a Buy rating and $150 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the company announced this morning that one of the two primary endpts of the Phase 3 REGENERATE trial in F2/F3 NASH was met w/ the highest dose tested (25mg QD Obeticholic... More
